Skip to main content
. 2014 Jul 2;91(1):138–145. doi: 10.4269/ajtmh.13-0595

Table 1.

Clinical presentation of DENV-infected patients by main serotypes*

Patients characteristics Total population N = 697 DENV-1 N = 160 DENV-2 N = 366 DENV-4 N = 171
Age, median years (Q1–Q3) 35 (23–50) 31 (21–46) 36 (24–50) 36 (24–53)
Sex ratio (M/F) 0.85 0.84 0.89 0.76
Clinical and biological manifestations
 Time of presentation, median days (Q1–Q3) 3 (2–5) 4 (3–5) 4 (2–5) 2 (1–4)
 Admitted during the critical phase, n (%) 204 (29.3) 35 (21.9) 144 (39.3) 25 (14.6)
 OR [95% CI] 1 2.3 [1.5–3.6] 0.6 [0.3–1.1]
 Gastrointestinal signs, n (%) 416 (60.6) 103 (65.2) 238 (65.8) 75 (44.9)
 OR [95% CI] 1 1.0 [0.7–1.5] 0.4 [0.3–0.7]
 Mucosal bleeding, n (%) 112 (16.1) 23 (14.4) 68 (18.6) 21(12.3)
 OR [95% CI] 1 1.3 [0.8–2.3] 0.8 [0.4–1.6]
 Plasma leakage, n (%) 100 (14.4) 16 (10.0) 73 (20.0) 11 (6.4)
 OR [95% CI] 1 2.2 [1.3–4.0] 0.6 [0.3–1.4]
 Platelet counts, median × 1,000/mL (Q1–Q3) 118 (64–175) 116 (86–164) 104 (38–163) 150 (110–190)
 Hematocrit, median % (Q1–Q3) 40 (38–44) 42 (39–44) 40 (37–43) 40 (38–43)
 ASAT, median IU/L (Q1–Q3) 56 (30–137) 57 (34–139) 67 (32–157) 39 (24–81)
Immune status
 Secondary infections, n (%) 387 (55.6) 75 (46.9) 224 (61.2) 88 (51.46)
 OR [95% CI] 1 1.8 [1.2–2.6] 1.2 [0.8–1.19]
Clinical forms
 Uncomplicated dengue, n (%) 376 (54.0) 87 (54.4) 174 (47.6) 115 (67.3)
 OR [95% CI] 1 0.8 [0.2–1.1] 1.7 [1.1–2.7]
 Intermediate severity, n (%) 169 (24.3) 48 (30.0) 92 (25.1) 29 (17.1)
 OR [95% CI] 1 0.8 [0.5–1.2] 0.5 [0.3–0.8]
 Severe dengue, n (%) 152 (21.8) 25 (15.6) 100 (27.3) 27 (15.8)
 OR [95% CI] 1 2.0 [1.3–3.3] 1.0 [0.6–1.8]
Clinical management
 Hospital stays > 1 day, n (%) 181 (26) 34 (21.3) 112 (30.6) 35 (20.5)
 OR [95% CI] 1 1.6 [1.1–2.5] 0.9 [0.6–1.6]
*

OR = odds ratio; CI = confidence interval.